Join to View Full Profile
2610 Aberdeen BlvdGastonia, NC 28054
Phone+1 980-442-4500
Fax+1 828-324-4154
Dr. Golshayan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Ali-Reza Golshayan, MD is an Oncologist currently located in Gastonia, NC. He specializes in hematology and medical oncology. He completed his Education and Residency in Internal Medicine at Cleveland Clinic Foundation from 2001 to 2004 followed by a fellowship in Hematology and Medical Oncology in 2007. Since 2018, he has been working as a Hematologist/Oncologist at Atrium Health. Doctor Golshayan has contributed to the medical field with multiple publications in highly reputable medical journals. His work has been recognized several times, as some of his articles have been cited by other publications. In 2012, he received the CMS Meaningful Use Stage 1 Certification from EpicCare Ambulatory EMR, Epic Systems Corporation.
Education & Training
Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 2004 - 2007- Cleveland Clinic FoundationResidency, Internal Medicine, 2001 - 2004
University of Vermont College of MedicineClass of 2001
Certifications & Licensure
NC State Medical License 2014 - 2026
SC State Medical License 2008 - 2015
OH State Medical License 2001 - 2008
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Publications & Presentations
PubMed
- Enzalutamide and Docetaxel in Combination With Androgen Deprivation for Men With Metastatic Hormone-Sensitive Prostate Cancer: ENZADA, a Phase II Trial.Earle F Burgess, Claud M Grigg, Danielle Boselli, James T Symanowski, AliReza Golshayan
Clinical Genitourinary Cancer. 2025-04-01 - 18 citationsLack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A...Andrea Necchi, Luigi Mariani, Salvatore Lo Vullo, Evan Y. Yu, Michael Woods
European Urology Focus. 2017-06-03 - 7 citationsRobot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist’s Perspective from a ...Andrea Necchi, Gregory R. Pond, Marc C. Smaldone, Sumanta K. Pal, Kevin Chan
European Urology Focus. 2017-03-31
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
